Revision history of "GENERIC MEDICINAL PRODUCT REVERSIBLE PLATELET RECEPTOR ANTAGONIST P2Y12 FOR THE TREATMENT OF ATHEROTHROMBOTIC EVENTS" (Q3175980)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

9 October 2024

  • curprev 10:4610:46, 9 October 2024DG Regio talk contribs 66,312 bytes −4 Changed label, description and/or aliases in pt
  • curprev 10:4610:46, 9 October 2024DG Regio talk contribs 66,316 bytes +70 Set a claim value: summary (P836): Este projeto visa dar continuidade à política de desenvolvimento de especialidades farmacêuticas genéricas destinadas ao tratamento de patologias com elevado impacto socioeconómico e propõe o desenvolvimento de uma nova especialidade farmacêutica genérica de ticagrelor, comprimidos revestidos por película de 60 mg e 90 mg, para coadministração com ácido acetil salicílico na prevenção de eventos aterotrombóticos em doentes adultos._x005 Atualmente, n...

22 March 2024

20 December 2023

12 June 2023

10 June 2023

18 August 2022

  • curprev 04:0504:05, 18 August 2022DG Regio talk contribs 63,892 bytes +42,629 Changed label, description and/or aliases in el, da, fi, mt, lv, sk, ga, cs, pt, et, hu, bg, lt, hr, sv, ro, sl, pl, nl, fr, de, it, es, and other parts: Adding translations: el, da, fi, mt, lv, sk, ga, cs, pt, et, hu, bg, lt, hr, sv, ro, sl, pl,

16 January 2022

17 December 2021

9 December 2021

4 December 2021

12 October 2021

  • curprev 18:3718:37, 12 October 2021DG Regio talk contribs 12,426 bytes +1,986 Created claim: summary (P836): This project aims to give continuity to the policy of development of generic proprietary medicinal products intended for the treatment of pathologies with high socio-economic impact, and proposes the development of a new generic proprietary medicinal product of ticagrelor, film-coated tablets of 60 mg and 90 mg, for co-administration with acetyl salicylic acid in the prevention of atherothrombotic events in adult patients._x005 There is currentl...
  • curprev 18:3718:37, 12 October 2021DG Regio talk contribs 10,440 bytes −1,986 Removed claim: summary (P836): This project aims to give continuity to the policy of development of generic proprietary medicinal products intended for the treatment of pathologies with high socio-economic impact, and proposes the development of a new generic proprietary medicinal product of ticagrelor, film-coated tablets of 60 mg and 90 mg, for co-administration with acetyl salicylic acid in the prevention of atherothrombotic events in adult patients._x005 There is curren...
  • curprev 18:3118:31, 12 October 2021DG Regio talk contribs 12,426 bytes +176 Changed label, description and/or aliases in en: translated_label
  • curprev 18:3118:31, 12 October 2021DG Regio talk contribs 12,250 bytes +1,986 Created claim: summary (P836): This project aims to give continuity to the policy of development of generic proprietary medicinal products intended for the treatment of pathologies with high socio-economic impact, and proposes the development of a new generic proprietary medicinal product of ticagrelor, film-coated tablets of 60 mg and 90 mg, for co-administration with acetyl salicylic acid in the prevention of atherothrombotic events in adult patients._x005 There is currentl...

10 October 2021

9 October 2021

8 October 2021